Literature DB >> 12076759

3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice.

Mike Bray1, Jo Lynne Raymond, Tom Geisbert, Robert O Baker.   

Abstract

3-deazaneplanocin A, an analog of adenosine, is a potent inhibitor of Ebola virus replication. A single dose early in infection prevents illness and death in Ebola virus-infected mice. The ability of this and similar compounds to block both RNA and DNA viruses has been attributed to the inhibition of a cellular enzyme, S-adenosylhomocysteine hydrolase (SAH), indirectly resulting in reduced methylation of the 5' cap of viral messenger RNA. However, we found that the protective effect of the drug resulted from massively increased production of interferon-alpha in Ebola-infected, but not uninfected mice. Peak interferon levels increased with the extent of disease at the time of treatment, indicating that production was boosted only in virus-infected cells. Ebola virus has been shown to suppress innate antiviral mechanisms of the type I interferon response. 3-deazaneplanocin A appears to reverse such suppression, restricting viral dissemination. Further development should focus on identifying adenosine analogues that produce a similar effect in Ebola virus-infected primates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12076759     DOI: 10.1016/s0166-3542(02)00018-9

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  39 in total

1.  Identification of a small-molecule entry inhibitor for filoviruses.

Authors:  Arnab Basu; Bing Li; Debra M Mills; Rekha G Panchal; Steven C Cardinale; Michelle M Butler; Norton P Peet; Helena Majgier-Baranowska; John D Williams; Ishan Patel; Donald T Moir; Sina Bavari; Ranjit Ray; Michael R Farzan; Lijun Rong; Terry L Bowlin
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 2.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

3.  Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1.

Authors:  St Patrick Reid; Charalampos Valmas; Osvaldo Martinez; Freddy Mauricio Sanchez; Christopher F Basler
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

4.  Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry.

Authors:  Maria V Yermolina; Jizhen Wang; Michael Caffrey; Lijun L Rong; Duncan J Wardrop
Journal:  J Med Chem       Date:  2011-01-04       Impact factor: 7.446

5.  Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2.

Authors:  Xuesen Zhao; Fang Guo; Mary Ann Comunale; Anand Mehta; Mohit Sehgal; Pooja Jain; Andrea Cuconati; Hanxin Lin; Timothy M Block; Jinhong Chang; Ju-Tao Guo
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

6.  Antiviral activity of a small-molecule inhibitor of filovirus infection.

Authors:  Travis K Warren; Kelly L Warfield; Jay Wells; Sven Enterlein; Mark Smith; Gordon Ruthel; Abdul S Yunus; Michael S Kinch; Michael Goldblatt; M Javad Aman; Sina Bavari
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

Review 7.  Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus.

Authors:  Ilhem Messaoudi; Gaya K Amarasinghe; Christopher F Basler
Journal:  Nat Rev Microbiol       Date:  2015-10-06       Impact factor: 60.633

8.  Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation.

Authors:  St Patrick Reid; Lawrence W Leung; Amy L Hartman; Osvaldo Martinez; Megan L Shaw; Caroline Carbonnelle; Viktor E Volchkov; Stuart T Nichol; Christopher F Basler
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

9.  Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.

Authors:  Andrea Rivera; Ilhem Messaoudi
Journal:  ACS Infect Dis       Date:  2015-03-30       Impact factor: 5.084

10.  Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus.

Authors:  Marcel Asper; Thomas Sternsdorf; Meike Hass; Christian Drosten; Antje Rhode; Herbert Schmitz; Stephan Günther
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.